UNSPSC 51352412: Ethinyl estradiol/ferrous fumarate/norgestrel

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.

UNSPSC 51352412 Ethinyl estradiol/ferrous fumarate/norgestrel is a Commodity code that covers a specific oral contraceptive combination product. State and local government buying under this code centers on pharmaceutical procurement through state health and human services agencies, Medicaid programs, and cooperative purchasing organizations that aggregate demand across multiple jurisdictions. The work involves securing reliable supply of this branded or generic formulation to support public health insurance beneficiaries, employees, and retirees. Issuing bodies include state health departments, state employee benefit programs, multistate cooperative purchasing alliances, and health and human services commissions. The mix spans administrative entities managing pharmacy benefit programs and their direct procurement relationships with pharmaceutical manufacturers and authorized wholesalers.

Recent activity shows two distinct contracting approaches. The Texas Health and Human Services Commission posted RFI HHS0017013 in March 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager and wholesale channels; responses were due April 3, 2026. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. MMCAP's solicitation requires NDC-specific pricing, cGMP and DSCSA compliance, contractual relationships with at least two of three named authorized wholesalers, and performance penalties ranging from $200 to $1,500 per violation. Recent opportunities concentrate in the Upper Midwest and Texas, with procurement activity driven by state health agencies restructuring pharmacy benefit administration and cooperative purchasing organizations consolidating demand for cost management.